Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with ...

Deep Apple Therapeutics, Inc. announced today a research collaboration and exclusive worldwide license agreement with Novo ...

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.

Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk ...

Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research ...

Deep Apple collaborates with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases: South San Francisco, California Thursday, June 12, 2025, 18:00 Hr ...

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity. U.S.-based Deep ...

Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases ...